Treatment efficacy and safety of low dose seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis: Twelve-week interim analysis of an international, randomized, dose ranging, phase 2 study.
- Publication date
- 1 January 2017
- Publisher
- Henry Ford Health System Scholarly Commons